EMEA-002292-PIP01-17
Key facts
Active substance |
Rovalpituzumab tesirine
|
Therapeutic area |
Oncology
|
Decision number |
P/0116/2018
|
PIP number |
EMEA-002292-PIP01-17
|
Pharmaceutical form(s) |
Powder and solvent for concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of lung carcinoma (small cell and non-small cell carcinoma)
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
AbbVie Ltd
E-mail: paediatricteam@abbvie.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|